0001209191-23-059628.txt : 20231222 0001209191-23-059628.hdr.sgml : 20231222 20231222184518 ACCESSION NUMBER: 0001209191-23-059628 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231221 FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pizzuti Dana CENTRAL INDEX KEY: 0001948238 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 231511079 MAIL ADDRESS: STREET 1: C/O CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-21 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001948238 Pizzuti Dana C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 0 1 0 0 Chief Med and Dev Officer 0 Common Stock 2023-12-21 4 M 0 9583 16.89 A 15494 D Common Stock 2023-12-21 4 S 0 9583 34.57 D 5911 D Non-qualified stock option (Right to Buy) 16.89 2023-12-21 4 M 0 9583 0.00 D 2032-10-10 Common Stock 9583 220417 D Includes 1,411 shares acquired under the Issuer's Employee Stock Purchase Plan. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $34.57 per share. The range of sales prices on the transaction date was $34.50 to $34.67 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Marc Wilson, as attorney-in-fact 2023-12-22